Insight Molecular Diagnostics

Yahoo Finance • yesterday

Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q1 2026 MANAGEMENT VIEW * "Since submitting GraftAssureDx to the FDA in late March, we've had a high degree of engagement from them and expect that, that will continue as we... Full story

Yahoo Finance • 2 months ago

Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx

Earnings Call Insights: Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 MANAGEMENT VIEW * CEO Joshua Riggs announced the submission of GraftAssureDx to the FDA, emphasizing, “we are, to our knowledge, the first dd-cfDNA assay to be s... Full story

Yahoo Finance • 7 months ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product adoption across geographies in transplantation, oncology and immunology NASHVILLE, T... Full story

Yahoo Finance • 7 months ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring

American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid overtreatment and preserve pa... Full story

Yahoo Finance • 8 months ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday,... Full story

Yahoo Finance • 8 months ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker for transplanted organ rejection (dd... Full story

Yahoo Finance • 9 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Inform... Full story

Yahoo Finance • 9 months ago

IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “Democratizi... Full story

Yahoo Finance • 9 months ago

Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements

Insight Molecular Diagnostics (IMDX) provided an in-depth view of its Q2 2025 performance during its earnings call on August 11, 2025. The company reported laboratory services revenue slightly below its target, alongside strategic product... Full story

Yahoo Finance • 9 months ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in J... Full story

Yahoo Finance • 9 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMD... Full story

Yahoo Finance • 10 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Ant... Full story

Yahoo Finance • 11 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was pre... Full story